We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+63.92%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
+$364M
Cap. Flow
+$152M
Cap. Flow %
10.45%
Top 10 Hldgs %
51.41%
Holding
99
New
31
Increased
26
Reduced
24
Closed
13

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$65.2M
2
ABVX
Abivax
ABVX
+$26.1M
3
QURE icon
uniQure
QURE
+$15.9M
4
DHR icon
Danaher
DHR
+$15.1M
5
PODD icon
Insulet
PODD
+$14.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$43.8M
2
INSP icon
Inspire Medical Systems
INSP
+$21.3M
3
IQV icon
IQVIA
IQV
+$15.4M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$15.3M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.94%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGEN icon
26
Repligen
RGEN
$7.44B
$14M 0.97%
105,087
+86,467
+464% +$10.5M
NAMS icon
27
NewAmsterdam Pharma
NAMS
$3.47B
$13.9M 0.96%
488,592
+74,162
+18% +$1.78M
RNAM
28
DELISTED
Avidity Biosciences
RNAM
$13.2M 0.91%
+302,911
New +$12.2M
NVO
29
Novo Nordisk
NVO
$216B
$12.1M 0.83%
+217,708
New +$12.7M
ILMN icon
30
Illumina
ILMN
$29.4B
$11.7M 0.81%
123,674
-74,910
-38% -$7.43M
AVTR icon
31
Avantor
AVTR
$7.81B
$11.5M 0.8%
924,442
-601,722
-39% -$7.75M
LQDA icon
32
Liquidia Corp
LQDA
$7.67B
$11.1M 0.76%
486,021
+127,193
+35% +$2.76M
MNKD icon
33
MannKind Corp
MNKD
$1.28B
$11M 0.76%
2,042,727
+1,345,017
+193% +$5.9M
BCRX icon
34
BioCryst Pharmaceuticals
BCRX
$2.37B
$10.4M 0.72%
1,373,625
+165,987
+14% +$1.38M
SPRY icon
35
ARS Pharmaceuticals
SPRY
$590M
$9.81M 0.68%
+976,511
New +$14M
ICLR icon
36
Icon
ICLR
$12.8B
$9.63M 0.66%
55,025
-9,562
-15% -$1.6M
REGN icon
37
Regeneron Pharmaceuticals
REGN
$68.8B
$9.4M 0.65%
16,720
+3,466
+26% +$1.96M
EOLS icon
38
Evolus
EOLS
$394M
$9.06M 0.62%
1,475,109
+304,798
+26% +$2.38M
EWTX icon
39
Edgewise Therapeutics
EWTX
$4.39B
$8.15M 0.56%
502,234
+109,495
+28% +$1.55M
CNC icon
40
Centene
CNC
$31.3B
$8.01M 0.55%
224,550
-174,176
-44% -$5.26M
BMRN icon
41
BioMarin Pharmaceuticals
BMRN
$11.5B
$7.94M 0.55%
+146,642
New +$8.39M
ARDX icon
42
Ardelyx
ARDX
$1.24B
$7.88M 0.54%
+1,429,377
New +$7.76M
BIIB icon
43
Biogen
BIIB
$29.9B
$7.25M 0.5%
+51,765
New +$7M
CPRX
44
DELISTED
Catalyst Pharmaceutical
CPRX
$6.91M 0.48%
+350,812
New +$7.21M
DVAX
45
DELISTED
Dynavax Technologies
DVAX
$6.89M 0.47%
693,527
-503,662
-42% -$5.24M
UTHR icon
46
PUT
United Therapeutics
UTHR
$26.3B
$6.79M 0.47%
+16,200
New +$5.45M
ISRG icon
47
Intuitive Surgical
ISRG
$121B
$6.45M 0.44%
+14,426
New +$6.92M
ETNB
48
DELISTED
89bio
ETNB
$5.77M 0.4%
392,441
+156,451
+66% +$1.59M
HQY icon
49
HealthEquity
HQY
$7.91B
$4.96M 0.34%
52,388
-103,480
-66% -$9.74M
GPCR icon
50
Structure Therapeutics
GPCR
$3.49B
$4.66M 0.32%
166,391
+67,053
+67% +$1.34M
1
2
3 4

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Eversept Partners held 99 positions worth $1.45B, up 33% from $1.09B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Eversept Partners deployed $152M of net new capital in Q3 2025, opening 31 new positions and adding to 26 existing holdings. Its largest new stake was Abivax: 426,499 shares worth $36.2M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Natera, an estimated $43.8M trimmed.

  • Eversept Partners's largest Q3 2025 buy was Abivax: 426,499 shares worth $36.2M.
  • Eversept Partners added most to United Therapeutics in Q3 2025, an estimated $65.2M increase.
  • Eversept Partners's biggest Q3 2025 reduction was Natera, cutting an estimated $43.8M.
  • Eversept Partners fully exited Inspire Medical Systems in Q3 2025, selling an estimated $21.3M.
  • Eversept Partners's ten largest holdings make up 51% of its $1.45B portfolio in Q3 2025.
  • Eversept Partners opened 31 new positions and closed 13 in Q3 2025.
  • Eversept Partners's portfolio value rose 33% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2025, filed 14 Nov 2025.